Chemical apparatus and process disinfecting – deodorizing – preser – Analyzer – structured indicator – or manipulative laboratory... – Sample mechanical transport means in or for automated...
Reexamination Certificate
1998-08-28
2001-10-02
Scheiner, Laurie (Department: 1648)
Chemical apparatus and process disinfecting, deodorizing, preser
Analyzer, structured indicator, or manipulative laboratory...
Sample mechanical transport means in or for automated...
C530S387100, C435S005000, C435S810000, C436S513000, C436S548000
Reexamination Certificate
active
06296807
ABSTRACT:
The invention relates to new virus forms capable of causing lymphadenopathies which are capable of then developing into acquired immuno-deficiency syndrome (AIDS). The invention also applies to antigens which may be obtained from these viruses and other viruses having certain properties in common with them. It also concerns antibodies which may be induced against these various antigens. Lastly, the invention relates to using these antigens or antibodies in diagnosing certain AIDS forms and, with respect to some of these AIDS forms, to producing immunizing and vaccinating compositions against these retroviruses such as purified proteins, glyco-proteins, recombinant proteins or synthetic peptides.
An article by F. Barre-Sinoussi et al. in Science, Vol 220: pp 868-871 [1983] describes the isolation of the first retrovirus which was known to be responsible for AIDS. European Patent Application 138,667 specifically describes diagnosis of AIDS and pre-AIDS by detection of the presence of antibodies against the virus through the use of certain virus extracts and particularly through the use of some of the viral proteins. This retrovirus is known generally as LAV. Since that time, other similar strains and variations of LAV have been isolated. Illustrative strains include HTLV-III and ARV. The expression “LAV-I” has been coined to cover these designations and the corresponding viral strains. Thus, the set of viruses which are identical with or close to the initial isolate shall be called herein “LAV type 1” or “LAV-I”.
The “LAV” set may be defined as a set of viruses either causing generalized and persistent polyadenopathies, or AIDS, and having in vitro a tropism for T4 cells wherein this retrovirus induces a cytopathogenic effect. These retroviruses have been found to be distinct from the other already known human retoviruses (HTLV-I and HTLV-II).
Even though the LAV virus does vary genetically rather substantially, the diverse strains isolated to-date from African, Haitian, European and American patients have in common certain antigen sites on their main proteins: p25 core protein; gp 110 envelope glyco-protein; and gp 41-43 transmembrane protein. As a result, the prototype strain LAV-I deposited at COLLECTION NATIONALE DES CULTURES DE MICRO-ORGANISMES (CNCM) under No. 1-232 may be used as an antigen strain to detect antibodies for all types of affiliated patients regardless of origin. For example, the HTLV-III virus isolated by R. C. Gallo et al. which is presently being used to detect antibodies in blood donors and patients by means of ELISA, immunofluorescence, and “Western blot” (or immuno-print) techniques and RIPA (radio immuno-precipitation assay).
However it was found in serological research on patients; native to Guinea-Bissau and hospitalized in Portugal that some had seronegative or very weakly positive reactions to these tests using an LAV-I lysate, whereas they evinced the clinical and immunological symptoms of AIDS.
Starting with the cultured lymphocytes from one of these patients, a retrovirus was isolated which structure, when examined under the electron microscope, and protein contour in the SDS electrophoresis gel were generally even similar in their properties to those of LAV-I, however, this retrovirus is less related to the LAV-I both as regards the antigenic homology of its proteins and the homology of its genetic material than the other, previously identified LAV strains.
REFERENCES:
patent: 4520113 (1985-05-01), Gallo et al.
patent: 4588681 (1986-05-01), Sawada
patent: 4629783 (1986-12-01), Cosand
patent: 4647773 (1987-03-01), Gallo
patent: 4652599 (1987-03-01), Gallo
patent: 4708818 (1987-11-01), Montagnier et al.
patent: 4839288 (1989-06-01), Montagnier et al.
patent: 5030718 (1991-07-01), Montagnier et al.
patent: 5055391 (1991-10-01), Montagnier et al.
patent: 5135864 (1992-08-01), Montagnier et al.
patent: 5256561 (1993-10-01), Chin
patent: 5304466 (1994-04-01), DeLeys et al.
patent: 5670309 (1997-09-01), Norrby et al.
patent: 5889158 (1999-03-01), Montagnier et al.
patent: 0 185 444 (1986-06-01), None
patent: 0 187 041 (1986-07-01), None
patent: WO 84/04327 (1984-11-01), None
patent: WO 85/04897 (1985-11-01), None
patent: WO 86/01834 (1986-03-01), None
patent: WO 86/02382 (1986-04-01), None
patent: WO 86/02930 (1986-05-01), None
patent: WO 86/04423 (1986-07-01), None
patent: WO 87/02892 (1987-05-01), None
Barin et al., “Serological Evidence For Virus Related To Simian T-Lymphotropic Retrovirus III In Residents Of West Africa,”The Lancet, 1387-1389 (Dec. 21/28, 1985).
Kanki et al., “Serologic Identification and Characterization of a Macaque T-Lymphotropic Retrovirus Closely Related to HTLV-III,”Science, 228, 1199-1201 (1985).
Kanki et al., “Isolation of T-Lymphotropic Retrovirus Related to HTLV-III/LAV from Wild-Caught African Green Monkeys,”Science, 230, 951-954 (1985).
Clavel et al., “Virology. —LAV type II: A second Retrovirus Associated with AIDS in West-Africa,”C. R. Acad. Sc. Paris, 302, 485-488 (1986).
Kestler et al., “Comparison of Simian Immunodeficiency Virus Isolates,”Nature, 331, 619-622 (1988).
Essex et al., “Essex and Kanki Reply,”Nature, 331, 621-622 (1988).
Marx, “Probing the AIDS Virus and Its Relatives,”Science, 236, 1523-1524 (1987).
Daniel et al., “Isolation of T-Cell Tropic HTLV-III-Like Retrovirus from Macaques,”Science, 228, 1201-1204 (1985).
Fultz et al., “Isolation of a T-lymphotropic Retrovirus from Naturally Infected Sooty Mangabey Monkeys (Cercocebus atys)”,Proc. Natl. Acad. Sci., USA, 83, 5286-5290 (1986).
Clavel et al., “Isolation of a New Human Retrovirus from West African Patients with AIDS,”Science, 233, 343-346 (1986).
Kanki et al., “New Human T-Lymphotropic Retrovirus Related to Simian T-Lymphotropic Virus Type III,”Science, 232, 238-243 (1986).
Barre-Sinoussi et al., “Isolation of A T-Lymphotropic Retrovirus From A Patient At Risk For Acquired Immune Deficiency Syndrome (AIDS) ,”Science, 220, 868-871 (1983).
Clavel et al., “Molecular Cloning And Polymorphism Of The Human Immune Deficiency Virus Type 2,”Nature, 324, 691-695 (1986).
Gallo, “The AIDS Virus,”Scientific American, 47-56 (1987).
Gallo et al., 1988, Nature (London) 333:564.
Levy, 1993, Microbiol. Rev. 57:183-187, 211-213.
Los Alamos Database, 1990, in Human Retroviruses and AIDS, Meyers et al., eds., Los Alamos National Laboratory, new Mexico, pp. 1A1-1A3.
Norrby et al., 1998, “Type-specific site-directed human immunodeficiency virus serology”, in Vaccines 88, Cold Spring harbor Laboratory, pp. 335-339.
Strongin, W., 1992, “Sensitivity, specificity, and predictive value of diagnostic tests: definitions and clinical applications”, in Laboratory Diagnosis of Viral Invections, Lennette, ed., Marcel Dekker, Inc, New York, pp. 211-219.
Tedder et al., 1988, The Lancet, 2:927-931.
Hunt et al., 1990, AIDS Res. Human Retro. 6:883-898.
Coffin, J. et al., Science 232, 697 (May 9, 1986).
Brun-Vezinet Francoise
Clavel Francois
Guetard Denise
Montagnier Luc
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Institut Pasteur
Parkin Jeffery S.
Scheiner Laurie
LandOfFree
Kits for the detection of human immunodeficiency virus type... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kits for the detection of human immunodeficiency virus type..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kits for the detection of human immunodeficiency virus type... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2576458